Manufacturers: Kura Oncology
Ziftomenib is a member of a new class of drugs known as menin inhibitors. Blood Cancer United's Therapy Acceleration Program (TAP) provided early, critical support for the foundational work conducted at the University of Michigan, and played a key role in introducing that work to Kura Oncology, which then advanced the development of ziftomenib.
Ziftomenib is a member of a new class of drugs known as menin inhibitors. Blood Cancer United's Therapy Acceleration Program (TAP) provided early, critical support for the foundational work conducted at the University of Michigan, and played a key role in introducing that work to Kura Oncology, which then advanced the development of ziftomenib.
Menin inhibitor (blocks the interaction between menin and KMT2A/MLL fusion proteins)
FDA-approved targeted therapy for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation (approval date: November 13, 2025; brand name Komzifti).
1 associated conditions
